{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T10:25:38Z","timestamp":1769941538364,"version":"3.49.0"},"reference-count":32,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,10,9]],"date-time":"2022-10-09T00:00:00Z","timestamp":1665273600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K16443"],"award-info":[{"award-number":["19K16443"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008999","name":"Japanese Society of Clinical Pharmacology and Therapeutics","doi-asserted-by":"publisher","award":["Foreign Clinical Pharmacology Training Program\u2010 19"],"award-info":[{"award-number":["Foreign Clinical Pharmacology Training Program\u2010 19"]}],"id":[{"id":"10.13039\/501100008999","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:p>Fluoroquinolones and macrolides may, due to a potential drug\u2010drug interaction, increase the concentration of any concomitantly administered direct oral anticoagulant (DOAC) and thereby increase the risk of severe bleeding. However, clinical evidence for such an effect is scarce. The present study aimed to evaluate the association between the use of fluoroquinolones or macrolides and bleeding events in patients with concomitant DOAC use. This was a nationwide cohort study including 19\u2009288 users of DOACs in 2008\u20102018 using information from Swedish national health registers. We compared the incidence of bleeding events associated with use of fluoroquinolones or macrolides using doxycycline as a negative control. Cox regression was used to calculate crude and adjusted hazard ratios (aHRs) in time windows of various length of follow\u2010up after the start of antibiotic use. The incidence rates for fluoroquinolones and macrolides ranged from 12 to 24 and from 12 to 53 bleeding events per 100\u2009000 patients in the investigated time windows. The aHRs (95% confidence interval) for use of fluoroquinolones and macrolides were 1.29 (0.69\u20102.44) and 2.60 (0.74\u20109.08) at the concomitant window, 1.31 (0.84\u20102.03) and 1.79 (0.75\u20104.29) at 30\u2009days, and 1.34 (0.99\u20101.82) and 1.28 (0.62\u20102.65) at 150\u2009days, respectively. With regard to fluoroquinolones, the present study suggests that the risk of bleeding when combined with DOACs, if any, is small. Codispensation of macrolides in patients on DOACs was not associated with an increased risk of bleeding. However, due to the small number of macrolide users, the results must be interpreted with caution.<\/jats:p>","DOI":"10.1111\/bcp.15531","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T12:48:32Z","timestamp":1663073312000},"page":"887-897","source":"Crossref","is-referenced-by-count":8,"title":["Bleeding events among patients concomitantly treated with direct oral anticoagulants and macrolide or fluoroquinolone antibiotics"],"prefix":"10.1111","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1194-3568","authenticated-orcid":false,"given":"Tatsuya","family":"Yagi","sequence":"first","affiliation":[{"name":"Department of Medicine Solna, Centre for Pharmacoepidemiology, Karolinska Institutet Karolinska University Hospital  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Buster","family":"Mannheimer","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education at S\u00f6dersjukhuset Karolinska Institutet  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Reutfors","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Centre for Pharmacoepidemiology, Karolinska Institutet Karolinska University Hospital  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Ursing","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences Danderyd Hospital, Karolinska Institutet  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego Hernan","family":"Giunta","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Centre for Pharmacoepidemiology, Karolinska Institutet Karolinska University Hospital  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helle","family":"Kieler","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Centre for Pharmacoepidemiology, Karolinska Institutet Karolinska University Hospital  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Linder","sequence":"additional","affiliation":[{"name":"Department of Medicine Solna, Centre for Pharmacoepidemiology, Karolinska Institutet Karolinska University Hospital  Stockholm Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,10,9]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11\u20102301"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197583"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004179.pub2"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezw313"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1884"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2016.08.006"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020526"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euv309"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2119"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.160938"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028013504741"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/00498250802651984"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.24.201"},{"key":"e_1_2_10_15_1","volume-title":"LiverTox: Clinical and Research Information on Drug\u2010Induced Liver Injury","author":"Macrolide Antibiotics","year":"2012"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13936"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.1835"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.13883"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvz035"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1294"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102458\u201011\u2010450"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654\u2010017\u20100316\u20101"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2013.853430"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908\u20101581ST"},{"key":"e_1_2_10_25_1","unstructured":"Administration tFaD.Drug Development and Drug Interactions|Table of Substrates Inhibitors and Inducers.2020."},{"key":"e_1_2_10_26_1","unstructured":"FlockhartDA ThackerD McdonaldC DestaZ.The Flockhart Cytochrome P450 Drug\u2010Drug Interaction Table. In: Division of Clinical Pharmacology Indiana University School of Medicine 2021."},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1000087107"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2006.10.018"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15538"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2014.970166"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.6b00259"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euab091"},{"key":"e_1_2_10_33_1","unstructured":"WeistK MullerA MonnetD HeuerO.Surveillance of antimicrobial consumption in Europe 2012.2014. European Centre for Disease Prevention and Control [online] Stockholm Sweden. Available:http:\/\/ecdceuropaeu\/en\/publications\/Publications\/antimicrobial-consumptioneurope-esac-net-2012pdf[accessed 22\u2010May\u20102015]"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15531","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15531","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T08:44:32Z","timestamp":1692521072000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,9]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1111\/bcp.15531"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15531","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,9]]}}}